DAVID FOGELMAN to Everolimus
This is a "connection" page, showing publications DAVID FOGELMAN has written about Everolimus.
Connection Strength
0.047
-
Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
Score: 0.027
-
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
Score: 0.020